Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.

@article{Kawanami2014EfficacyAS,
  title={Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.},
  author={Toshinori Kawanami and Hiroshi Mukae and Shingo Noguchi and Kei Yamasaki and Kentarou Akata and Hiroshi Ishimoto and Kana Matsumoto and Kunihiko Morita and Kazuhiro Yatera},
  journal={Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
  year={2014},
  volume={20 12},
  pages={
          768-73
        }
}
INTRODUCTION Pneumonia is the third leading cause of mortality in Japan. In 2011, the use of meropenem (MEPM) at 3 g daily was approved to treat refractory infections in Japan. However, little has been reported on the clinical efficacy and safety of this regimen in Japanese patients with refractory infections. OBJECTIVES This study prospectively assessed the clinical efficacy and safety of MEPM (3 g daily) in Japanese patients with refractory pneumonia and/or intrapleural infections… CONTINUE READING
BETA

Topics from this paper.

Similar Papers

Loading similar papers…